Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.68 |
| ▸ | FADS1 | O60427 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.58 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | LTK | P29376 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.58 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.58 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.58 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564798 | 0.86 | EGFR (0.60) | EGFRFADS1LCKDYRK1AABCG2 | |
| SCHEMBL5569110 | 0.86 | EGFR (0.60) | EGFRFADS1LCKSRCDYRK1A | |
| SCHEMBL9017045 | 0.84 | TTBK1 (0.61) | EGFRFADS1LCKDYRK1AABCG2 | |
| SCHEMBL5568040 | 0.83 | EGFR (0.60) | EGFRFADS1LCKDYRK1AABCG2 | |
| SCHEMBL11092575 | 0.82 | EGFR (0.63) | EGFRFADS1LCKSRCDYRK1A | |
| SCHEMBL11091920 | 0.82 | TTBK1 (0.59) | EGFRFADS1LCKSRCAURKB | |
| SCHEMBL5566231 | 0.82 | SRC (0.65) | EGFRSRCDYRK1AERBB2GLA | |
| SCHEMBL14027230 | 0.81 | EGFR (0.75) | EGFRFADS1LCKDYRK1AABCG2 | |
| Hydrochloric Acid SCHEMBL11089555 | 0.81 | TTBK1 (0.58) | EGFRFADS1LCKSRCAURKB | |
| Hydrochloric Acid SCHEMBL11088198 | 0.81 | EGFR (0.62) | EGFRFADS1LCKSRCDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885FADS1 4484/4885LCK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.